The association between methimazole tapering and intractable Graves' disease in children
Pediatrics International · 2024
DOI: 10.1111/ped.15823 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatrics International, 2024. Verfasst von Sung Eun Kim und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, College of Medicine, Incheon St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Graves Disease, Methimazole, Antithyroid Agents. Die Arbeit nennt 35 Literaturangaben.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
The aim of this study was to find predictive factors for intractable Graves' disease (GD).
Methods
Ninety‐three GD patients who visited two pediatric endocrinology clinics from March 2009 to August 2019 were involved in this study. Data were collected on the methimazole (MZ) dosages prescribed from their first visits to their fifth visits. The amount of tapered dosage was presented as a “tapering velocity” (dosage difference (mg/m 2 )/follow‐up interval (months)). The relationship between the tapering velocity and the remission rate of GD was analyzed. Remission of GD was defined as having a total period of MZ treatment less than 5 years with no relapse after MZ withdrawal for at least more than a year.
Results
Of 93 patients diagnosed with GD, 26 patients (28.0%) were classified as the “remission group” and 67 (72.0%) were classified as the “intractable group.” The frequency of goiter was significantly higher in the intractable group ( p = 0.031). Multivariate logistic analysis revealed that the tapering velocity change from the first to the fifth visit significantly influenced the risk of intractable GD: odds ratio (OR) = 0.598, 95% confidence interval (CI) 0.413–0.865, p = 0.006. An accompanying goiter at the time of diagnosis (OR = 4.706 95% CI 1.315–16.847, p = 0.017) and thyroid stimulation hormone receptor antibody titer (OR = 1.032 95% CI 1.002–1.062, p = 0.034) were also found to be independent factors associated with intractable progress in GD.
Conclusion
Difficulty in tapering the MZ dosage in the first 4 months of treatment was an independent predicting factor for intractable GD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, College of Medicine, Incheon St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea.
- Department of Pediatrics, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea.
- Department of Pediatrics, College of Medicine, Eunpyeong St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea.
- Department of Pediatrics, College of Medicine, St. Vincent's Hospital, The Catholic University of Korea, Seoul, Republic of Korea.
- Department of Pediatrics, College of Medicine, Bucheon St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea.
- Department of Pediatrics, College of Medicine, Yeouido St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea.
ORCID-Profile: Sung Eun Kim
Zitieren
APA
Kim, S. E., Park, S. J., Sim, S. Y., Kim, S. K., Ahn, M. B., Kim, S. H., Cho, W. K., Cho, K. S., Jung, M. H., & Suh, B. K. (2024). The association between methimazole tapering and intractable Graves' disease in children. Pediatrics International. https://doi.org/10.1111/ped.15823
Vancouver
Kim SE, Park SJ, Sim SY, Kim SK, Ahn MB, Kim SH, et al. The association between methimazole tapering and intractable Graves' disease in children. Pediatrics International. 2024. doi:10.1111/ped.15823
BibTeX
@article{Kim2024,
author = {Kim, Sung Eun and Park, Su Jin and Sim, Soo Yeun and Kim, Seul Ki and Ahn, Moon Bae and Kim, Shin Hee and Cho, Won Kyoung and Cho, Kyoung Soon and Jung, Min Ho and Suh, Byung-Kyu},
title = {The association between methimazole tapering and intractable Graves' disease in children},
journal = {Pediatrics International},
year = {2024},
doi = {10.1111/ped.15823}
}
EUVIMED